Executive Vice President, Chief Commercial Officer and Head of Business Development · Karyopharm Therapeutics Inc. (KPTI)

Sohanya Cheng

A named executive officer of Karyopharm Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,094,829

Salary $546,000Stock awards $315,794

FY2023: $1,193,414

3rd of 3 named executive officers at Karyopharm Therapeutics by FY2024 total.

3 named officers on file for Karyopharm Therapeutics, FY2024

Sohanya Cheng’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • KPTI’s disclosed peer group of 1 company

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Karyopharm Therapeutics’s whole pay program stands against its peers

  • Karyopharm Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KPTI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 14, 2025 (DEF 14A).

Free

Get Sohanya Cheng’s full pay file as a PDF — free

More than this page: up to 10 years of Sohanya’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Sohanya Cheng compensation by year

Karyopharm Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Karyopharm Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024
Salary$457,333$513,688$546,000
Bonus$0$0$0
Stock awards$1,019,520$450,465$315,794
Option awards$928,902$0$0
Non-equity incentive$193,048$202,650$214,373
Pension and deferred compensation$0$0$0
All other$13,915$26,611$18,662
Total$2,612,718$1,193,414$1,094,829

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Karyopharm Therapeutics Inc. DEF 14A filed April 14, 2025, accession 0000950170-25-053511, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Karyopharm Therapeutics Inc. filed document, accession 0000950170-25-053511. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2025.

$2.6M
$1.2M
$1.1M
FY22
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU13,263$134,487—
RSU4,444$45,062—
PSU2,842$28,818—
RSU2,800$28,392—
PSU1,889$19,154—
Option1,042—$154.80
Option2,101—$154.95

Per the Outstanding Equity Awards at Fiscal Year-End table in Karyopharm Therapeutics Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Karyopharm Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Richard PaulsonPresident and Chief Executive Officer$2,069,341
Reshma RangwalaExecutive Vice President, Chief Medical Officer and Head of Research$1,124,444
Sohanya Cheng · this pageExecutive Vice President, Chief Commercial Officer and Head of Business Development$1,094,829

The full Karyopharm Therapeutics compensation record

free company brief

This page is one person within Karyopharm Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Karyopharm Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Karyopharm Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Sohanya Cheng's compensation dossier · One-time report. No refunds.